Could we utilise extracellular vesicle to direct a more personalised therapy for metastatic cancers?

What is it about?

Extracellular vesicles (EVs), vesicles secreted by cells, have been explored as biomarker for cancers including prostate cancer. In this paper, we review the relevance of EVs as biomarker to help clinicians and advanced cancer patients to decide on what therapy will benefit them the most.

Featured Image

Why is it important?

This review highlights the potential to utilise a subpopulation of extracellular vesicles that responded towards hormone manipulation, a treatment regime widely employed in prostate cancer. We also show a correlation between circulating tumour cells (CTCs) and circulating EVs. The CTCs count has been employed in the clinic to indicate the prognosis of metastatic cancers.